Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. With lupus, the body's immune system targets its own body tissues. Lupus nephritis happens when lupus involves the kidneys. A preliminary analysis of the safety data did not reveal any new or unexpected safety signals in patients receiving Rituxan. Two types of blood pressure lowering medications.
Renal involvement is a serious complication of systemic lupus erythematosus, and proliferative lupus nephritis (WHO classes III and IV) has poor outcomes. With the advent of induction therapy with cyclophosphamide, the survival of patients has improved, with 5-year survival for class IV lupus nephritis at 82%. 25-30% of patients of diffuse proliferative lupus nephritis will reach end-stage renal disease (ESRD) over 20 years of follow-up.
People with lupus nephritis that is causing high blood pressure may need to take medications that lower their blood pressure and can also significantly slow the progression of kidney disease.Many people require two or more medications to control their blood pressure. In addition to an ACE inhibitor or an ARB, a diuretic—a medication that helps the kidneys remove fluid from the body—may be prescribed. Beta blockers, calcium channel blockers, and other blood pressure medications may also be needed.
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III study of Rituxan® (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. The primary endpoint evaluated improvements in kidney response as measured by standard laboratory tests used to assess kidney health.